Cytonix Corp. Receives Exclusive License from the National Institutes of Health for Single Molecule DNA Detection

Beltsville, MD, March 03, 2007 --( Cytonix Corporation announced today that it has signed an exclusive license with the National Institutes of Health (NIH) for a novel method of sampling, amplifying and quantifying nucleic acids and for the production of nanoliter devices needed for the application of this technology.  This technology allows Cytonix to capture a single nucleic acid molecule in a nanoarray vastly facilitating the detection and identification of signature DNA or RNA molecules.  The nanoarrays from Cytonix will make it possible to count the number of DNA or RNA molecules captured as the unit of absolute quantity.

James F. Brown, VP of Cytonix is a co-inventor of  this patented technology: U.S. patent No. 6,143,496 (issued November 7, 2000 entitled “Methods of Sampling, Amplifying and Quantifying Segment of Nucleic Acid” and for U.S. Patent Application Serial No. 10/131,854 (‘854, filed April 25, 2002, publication No. 20020164820), entitled “Method of sampling, amplifying and quantifying segment of nucleic acid, polymerase chain reaction assembly having nanoliter-sized sample chambers, and method of filling assembly.”  According to Mr. Brown, “this technology provides Cytonix Corporation the unique ability to identify a single molecule of  contaminating DNA in food, water or blood by simply counting the number of fluorescent wells in a nanoarray chamber and provides for the first time a true quantitative procedure for measuring nucleic acids.” This technology offers an alternative to traditional real time quantitative-PCR (qPCR) as a means of quantifying nucleic acids and treats every nucleic acid molecule as an individual, overcoming a major limitation of current PCR procedures in detecting rare sequence differences.

Detection and quantification methods based on single molecule detection have exquisite sensitivity, immense dynamic range, and unprecedented quantitative precision. Cytonix’s new ultra-sensitive technology is easier to use, considerably faster, more accurate and less expensive than current PCR methods, accelerating the development of applications in diagnosis of human disease, forensics, environmental monitoring and detection of pathogens during an emerging infectious disease or a deliberate biological attack.

Since 1985, Cytonix Corporation patents and technologies have enabled the development of innovative products for life sciences, medical, aerospace and communications industries worldwide.

Cytonix Corporation
Elaine Lanza, PhD
703 929-5324